CURRICULUM VITAE
James Franklin Fries, M.D.

Born: August 25, 1938
Married: Sarah Elizabeth Tilton

EDUCATION

1960 A.B. Stanford University, Stanford, California
1964 M.D. The Johns Hopkins University School of Medicine, Baltimore, Maryland
1970 Diplomate, American Board of Internal Medicine
1974 Diplomate, American Board of Rheumatology

TRAINING AND EXPERIENCE

1964-1966 Resident in Medicine, Johns Hopkins Hospital, Baltimore, Maryland
1966-1968 Fellow, Connective Tissue Disease Division, Johns Hopkins Hospital, Baltimore, Maryland
1968-1969 Resident, Department of Medicine, Stanford University School of Medicine
1969-1971 Instructor in Medicine, Stanford University School of Medicine
1971-1977 Assistant Professor of Medicine, Stanford University School of Medicine
1977-1993 Associate Professor of Medicine, Stanford University School of Medicine
1993- Professor of Medicine, Stanford University School of Medicine

AWARDS AND FELLOWSHIPS

1966-1968 Johns Hopkins Hospital, NIH Training Grant in Arthritis (Fellow)
1969-1971 Clinical Scholar, Carnegie Foundation
1971-1978 Postdoctoral Fellow, Clinical Scholar, Arthritis Foundation
1978-1979 Fellow, Center for Advanced Study in the Behavioral Sciences, Stanford University
2000-2001 Fellow, Center for Advanced Study in the Behavioral Sciences, Stanford University

SELECTED VISITING PROFESSORSHIPS AND KEYNOTE ADDRESSES

1981- Harvard 1981; Johns Hopkins Univ 1982; Mayo Clinic 1983,1992; Institute of Medicine 1983; Toronto 1983, 1992; American Gerontological Association 1985; Duke Univ 1985; McMaster Univ 1985, 1990; Cairo 1986; New Zealand Rheumatism Assoc 1986; Australian Rheumatism Assoc 1986; Univ of Berlin 1987; UCLA 1987; Keio 1988; Free Max Planck Institute 1988; Association for Behavioral Medicine 1989; Leuven 1989; Groningen 1990; Stockholm 1990; Compression of Morbidity Asilomar Conference 1990; Johns Hopkins Centennial Symposium 1990; Sandoz Lecturer in Gerontology 1990; USC 1990; AHCPR 1992; Centers for Disease Control 1992; European League Against Rheumatism 1992; Maastricht 1992; Univ of Pennsylvania 1992; Compression of Morbidity Conference 1993; Erasmus University 1993; American Hospital Association 1994; Prague 1994; Royal College of Medicine of Scotland 1994; HHS, EULAR, Amsterdam 1995; Future of Health, Stockholm 1995; DOD, San Antonio 1996; Health Care 2005, Karolinska 1996; Bayer Centennial, Venice 1997; Hong Kong 1997; ILAR, Singapore 1997; Institute of Medicine 1997; National Health Service, UK 1998; Special Surgery 1999; EULAR, Turku 2000; Health promotion 2000, 2001; NYU 2000; EULAR, Prague 2001; EULAR, Stockholm 2002; ILAR, Edmonton 2001; IUSSP, Bahia 2001; William Harvey 2002; Regenstreiff 2002; Barcelona 2002; Oxford WHO, 2003, 2004; Florence SIGG, 2003, Sidney Katz Lecture on Aging, Brown University 2004, Brisbane, 2004; Dresden, 2004; Paris, 2004; Aging/GSA, 2004; McGill, Aging 2005.

SOCIETIES AND HONORS

Fellow, American College of Rheumatology
Fellow, American College of Physicians
Editorial Board, *Journal of Rheumatology*
Editorial Board, *Am J Health Promotion*
Editorial Board, *J. Clinical Rheumatology*
Diplomate, American Board of Internal Medicine (1970)
Diplomate, Subspecialty Board of Rheumatology (1975)
Founding Fellow, *American College of Informatics*
Chairman, Healthtrac Foundation (1991-)
White House, The Health Project. Board of Directors, Executive Committee, C. Everett Koop National Health Award (1994-)
Director, Health Promotion Task Force, 2000-
Research Hero, Arthritis Foundation, 2001
Master of Rheumatology, 2003, Am. Col. Rheum.
Inaugural Research Award, Italian Gerontology, 2003

PUBLISHED REFEREED JOURNAL ARTICLES

1. **Fries JF**, Richter C. Lung cancer. *Arch Intern Med* 1965;113:624-634.

2. **Fries JF**, Richter C. Vernderungen des elektrischen hautwiderstandes bei bronchialkarzinomen. *Fortschr Med* 1965;83:647-650.

3. **Fries JF**, Siraganian R. Sulfonamide hepatitis. *N Engl J Med* 1966;274:95-97.

4. **Fries JF**. Physiologic studies in systemic sclerosis (scleroderma). *Arch Intern Med* 1969;123:22-25.

5. D'Angelo W, **Fries JF**, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). *Am J Med* 1969;46:428-440.

6. **Fries JF**. Experience counting in sequential computer diagnosis. *Arch Intern Med* 1970;127:647-651.

7. **Fries JF**, Hoopes JE, Shulman LE. Reciprocal skin grafts in systemic sclerosis (scleroderma). *Arthritis Rheum* 1971;14:571-578.

8. **Fries JF**. Time-oriented patient records and a computer databank. *JAMA* 1972;222:1536-1542.

9. **Fries JF**, Siegel RC. Testing the "preliminary criteria for classification of SLE." *Ann Rheum Dis* 1973;32:171-177.

10. **Fries JF**, Sharp GC, McDevitt HO, Holman HR. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. *Arthritis Rheum* 1973;16:154-162.

11. **Fries JF**, Lindgren JA, Bull JM. Scleroderma-like lesions and the carcinoid syndrome. *Arch Intern Med* 1973;131:550-553.

12. Stern MP, Kolterman OG, **Fries JF**, McDevitt HO, Reaven GM. Adrenocortical steroid treatment of rheumatic diseases. *Arch Intern Med* 1973;132:97-101.

13. **Fries JF**, Britton MC. Fenoprofen calcium in rheumatoid arthritis. *Arthritis Rheum* 1973;16:629-634.

14. Coplon N, Siegel R, **Fries JF**. Hemodialysis in end-stage lupus nephritis. *Trans Amer Soc Artif Int Organs* 1973;16:629-634.

15. **Fries JF**, Hess EV, Klinenberg J. A standard database for rheumatic diseases. *Arthritis Rheum* 1974;17:327-336.

16. **Fries JF**, Powers R, Kempson RL. Late-stage lupus nephropathy. *J Rheumatol* 1974;1:166-175.

17. Harrell GS, Gold JA, **Fries JF**, Bradley B, Zboralske FF. Intraluminal esophageal re-warming in normals and in patients with connective tissue disease. *Invest Radiol* 1974;9:186-192.

18. Siegel RC, **Fries JF**. Intra-arterially administered reserpine and saline in scleroderma. *Arch Intern Med* 1974;134:515-518.

19. **Fries JF**. Alternatives in medical record formats. *Med Care* 1974;12:871-881.

20. **Fries JF**, Weyl S, Holman HR. Estimating prognosis in systemic lupus erythematosus. *Am J Med* 1974;57:561-565.

21. Weyl S, **Fries JF**, Wiederhold G, Germano F. A modular self-describing clinical databank system. *Comput Biomed Res* 1975;8:279-293.

22. Wiederhold G, **Fries JF**, Weyl S. Structured organization of clinical data bases. *AFIPS Conference and Proceedings* 1975;44:479-485.

23. Miller III JJ, **Fries JF**. Simultaneous vasculitis in a mother and newborn infant. *J Pediatrics* 1975;87:443-445.

24. Calin A, **Fries JF**. Striking prevalence of ankylosing spondylitis in "healthy" W27 positive males and females. *N Engl J Med* 1975;293:835-839.

25. Rudd P, **Fries JF**, Epstein WV. Irreversible bone marrow failure with chlorambucil. *J Rheumatol* 1975;2:421-429.

26. **Fries JF**, Mitchell DM. Joint pain or arthritis. *JAMA* 1976;235;199-204.

27. Calin A, **Fries JF**. An "experimental" epidemic of Reiter's syndrome revisited: Follow-up evidence on genetic and environmental factors. *Ann Intern Med* 1976;84:564-566.

28. **Fries JF**, Hess EV, Klinenberg JR. A uniform database for rheumatic diseases. *Arthritis Rheum* 1976;19:645-648.

29. **Fries JF**, Britton MC. Some problems in the interpretation of clinical trials: Long-term parallel study of fenoprofen in rheumatoid arthritis. *J Rheumatol* 1976;2,3(suppl):61-66.

30. Calin A, **Fries JF**. The single hot joint. *Compr Ther* 1976;2:4-10.

31. Calin A, **Fries JF**. Polyarthralgia and polyarthritis. *Compr Ther* 1976;2:11-16.

32. **Fries JF**, Calin A. Ankylosing spondylitis: Genetics versus environment. *Compr Ther* 1976;2:17-22.

33. Fri**es JF**. The clinical aspects of systemic lupus erythematosus. *Med Clin North Am* 1977;61:229-240.

34. Calin A, Porta J, **Fries JF**, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. *JAMA* 1977;237:2613-2614.

35. Calin A, **Fries JF**, Schurman DJ, Payne R. The close correlation between symptoms and disease expression in HLA B27 positive individuals. *J Rheumatol* 1977;4:277-281.

36. Petz LD, Powers R, **Fries JF**, et al. The in vivo metabolism of the third component of complement in systemic lupus erythematosus. *Arthritis Rheum* 1977;20:1304-1313.

37. McShane DJ, Porta J, **Fries JF**. Comparison of therapy in severe systemic lupus erythematosus employing stratification techniques. *J Rheumatol* 1978;5:51-58.

38. Liang MH, Schurman DJ, **Fries JF**. A patient-administered questionnaire for arthritis assessment. *Clin Orthop* 1978;131:123-129.

39. Liang MH, **Fries JF**. Asymptomatic hyperuricemia: The case for conservative management. *Ann Intern Med* 1978;88:666-670.

40. Wasner C, Cooke CR, **Fries JF**. Successful medical treatment of scleroderma renal crisis. *N Engl J Med* 1978;299:873-875.

41. **Fries JF**, Porta J, Liang MH. Marginal benefit of renal biopsy in systemic lupus erythematosus. *Arch Intern Med* 1978;138:1386-1389.

42. Dannenberg AL, Shapiro AR, **Fries JF**. Enhancement of clinical predictive ability by computer consultation. *Methods Int Med* 1979;18:10-14.

43. Loftus EF, **Fries JF**. Informed consent may be hazardous to health. *Science* 1979;204:11.

44. **Fries JF**. The patient as the ultimate physician extender: Take care of yourself. *Proceedings of the Fourth Illinois Conference on Medical Information Systems*, University of Illinois, May 11-14, 1979;183-188.

45. **Fries JF**. The approach to the rheumatic disease patient. *Compr Ther* 1979;5:8-15.

46. McShane DJ, Harlow A, Kraines RG, **Fries JF**. TOD: A software system for the ARAMIS data bank. *Computer* 1979;12:34-40.

47. **Fries JF**, McShane DJ. ARAMIS: A national chronic disease data bank system. *Proceedings of the 3rd Annual Symposium on Computer Applications in Medical Care IEEE*, Washington, DC, October 1979;798-801.

48. Masi AT, Medsger TA, Rodnan GP, **Fries JF**, et al. Methods and preliminary results of the scleroderma criteria cooperative study of the American Rheumatism Association. *Clin Rheum Dis* 1979;5:27-48.

49. Feigenson JS, **Fries JF**, Kunitz S, McShane DJ, Greenberg SD. Time-oriented functional profile: Practical applications in a stroke data base model. *Arch Phys Med Rehabil* 1979;60:512-516.

50. **Fries JF**, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-145.

51. Coles LS, Brown BW, Englehard C, Halpern J, **Fries JF**. Determining the most valuable clinical variables: A stepwise multiple logistic regression program. *Methods Inf Med* 1980;19:42-49.

52. Wasner CK, **Fries JF**. Treatment decisions in systemic lupus erythematosus. *Arthritis Rheum* 1980;23:283-286.

53. Subcommittee for Scleroderma Criteria of the ARA Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980;23:581-589.

54. **Fries JF**. Aging, natural death, and the compression of morbidity. *N Engl J Med* 1980;303:130-135.

55. Masi AT, Rodnan GP, Medsger TA, Altman RD, D'Angelo, **Fries JF**, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Bull Rheum Dis* 1981;31:1-6.

56. Wasner CK, Britton MC, Kraines RG, Kaye RL, Bobrove AM, **Fries JF**. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. *JAMA* 1981;246:2168-2172.

57. Mitchell DM, **Fries JF**. An analysis of the American Rheumatism Association criteria for rheumatoid arthritis. *Arthritis Rheum* 1982;25:481-487.

58. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, **Fries JF**, et al. A multi-center study of outcome in systemic lupus erythematosus. *Arthritis Rheum* 1982;25:601-617.

59. Feigenbaum PA, Medsger Jr TA, Kraines RG, **Fries JF**. The variability of immunologic laboratory tests. *J Rheumatol* 1982;9:408-414.

60. **Fries JF**. Long-term outcome, long term data. *Proceedings of the First Annual Conference of the American Association for Medical Systems and Informatics*, Washington DC, October 27-30, 1982;10-11.

61. **Fries JF**, Spitz PW, Young DY. The dimensions of health outcomes: The Health Assessment Questionnaire, disability and pain scales. *J Rheumatol* 1982;9:789-793.

62. Tan EM, Cohen AS, **Fries JF**, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-1277.

63. Coles LS, **Fries JF**, Kraines RG, Roth SH. From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs. *Am J Med* 1983;74:820-828.

64. **Fries JF**. Toward an understanding of patient outcome measurement. *Arthritis Rheum* 1983;26:697-704.

65. **Fries JF**. The assessment of disability: From first to future principles. *Br J Rheumatol* 1983;22(suppl):48-58.

66. **Fries JF**. The compression of morbidity. *Milbank Mem Fund Q* 1983;61:397-419.

67. **Fries JF**. Clinical criteria for diagnosing the spondylarthropathies. *J Musculoskeletal Medicine* 1983;1(1):57-61.

68. **Fries JF**. The chronic disease data bank: First to future directions. *J Med Philos* 1984;9:161-180.

69. Brown JF, Kazis LE, Spitz PW, Gertman P, **Fries JF**, Meenan RF. The dimensions of health outcomes: A cross-validated examination of health status measurement. *Am J Public Health* 1984;74:159-161.

70. **Fries JF**. Disease criteria for systemic lupus erythematosus. *Arch Intern Med* 1984;144:252-253.

71. **Fries JF**, Wasner C, Brown J, Feigenbaum P. A controlled trial of anti-hypertensive therapy in systemic sclerosis (scleroderma). *Ann Rheum Dis* 1984;43:407-410.

72. **Fries JF**. The compression of morbidity: Miscellaneous comments about a theme. *The Gerontologist* 1984;24:355-359.

73. **Fries JF**. Epidemiology of cancer in rheumatoid arthritis: Methodologic pitfalls. *Am J Med* 1985;78(Suppl 1A):12-14.

74. **Fries JF**, Bloch DA, Spitz PW, Mitchell DM. Cancer in rheumatoid arthritis: A prospective long-term study of mortality. *Am J Med* 1985;78(Suppl 1A):56-59.

75. **Fries JF**. The ARAMIS (American Rheumatism Association Medical Information System) Post-Marketing Surveillance Program. *Drug Information Journal* 1985;19:257-262.

76. **Fries JF**, Bloch D, Sharp JT, et al. Assessment of radiologic progression in rheumatoid arthritis: A randomized, controlled trial. *Arthritis Rheum* 1986;29:1-9.

77. **Fries JF**. The future of disease and treatment: Changing health condition, changing behaviors, and new medical technology. *Journal of Professional Nursing* 1986;2(1):10-19.

78. Lane NE, Bloch DA, Jones HH, Marshall WH, Wood PD, **Fries JF**. Long-distance running, bone density, and osteoarthritis. *JAMA* 1986;255(9):1147-1151.

79. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. *Arthritis Rheum* 1986;29(6):706-714.

80. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. *Arthritis Rheum* 1986;29(4):494-500.

81. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multi-center study of annual health service utilization and costs in rheumatoid arthritis. *Arthritis Rheum* 1986;29(4):488-493.

82. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA. Impact of specific therapy upon rheumatoid arthritis. *Arthritis Rheum* 1986;29(5):620-627.

83. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ, Fink CW, Hanson V, Jacobs JC, Masi AT, Schaller JG, Fries JF, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. *Arthritis Rheum* 1986;29(2):274-281.

84. Wolfe F, Kleinheksel SM, Spitz PW, Lubeck DP, Fries JF, Young DY, Mitchell D, Roth S. A multi-center study of hospitalization in rheumatoid arthritis: Frequency, medical-surgical admissions, and charges. *Arthritis Rheum* 1986;29(5):614-619.

85. Wolfe F, Kleinheksel SM, Spitz PW, Lubeck DP, Fries JF, et al. A multi-center study of hospitalization in rheumatoid arthritis: Effect of health care system, severity, and regional difference. *J Rheumatol*

1986;13(2):277-284.

86. Fries JF, McShane DJ. ARAMIS (The American Rheumatism Association Medical Information System): A prototypical national chronic-disease data bank. *West J Med* 1986;145:798-804.

87. Sherrer Y, Bloch D, Strober S, Fries J. Comparative toxicity of total lymphoid irradiation and immunosuppressive drug treated patients with intractable rheumatoid arthritis. *J Rheumatol* 1986;14(1):46-51.

88. Lane NE, Bloch DA, Wood PD, Fries JF. Aging, long-distance running, and the development of musculoskeletal disability. *Am J Med* 1987;82:772-780.

89. Sherrer Y, Bloch DA, Mitchell DM, Roth SH, Wolfe F, Fries JF. Disability in rheumatoid arthritis: Comparison of prognostic factors across three populations. *J Rheumatol* 1987;14:705-709.

90. Altman RD, Fries JF, Bloch DA, et al. Radiographic assessment of progression in osteoarthritis. *Arthritis Rheum* 1987;30(11):1214-1225.

91. Fries JF. An introduction to the compression of morbidity. *Gerontologica Perspecta* 1987;1:5-8.

92. Fries JF. Reduction of the national morbidity. *Gerontologica Perspecta* 1987;1:54-65.

93. Wolfe F, Fries JF. Moving toward internationally distributed databank systems for follow-up studies. *Clin Rheumatol* 1987;6(2):93-102.

94. Spitz PW, Fries JF. The present and future of comprehensive outcome measures for rheumatic diseases. *Clin Rheumatol* 1987;6(2):105-111.

95. Fries JF. Methodology of validation of criteria for SLE. *Scand J Rheumatol* 1987;(suppl 65):25-30.

96. Fries JF, Bloch DA, Segal MR, Spitz PW, Williams CA, Lane NE. Post-marketing surveillance in rheumatology: Analysis of purpura and upper abdominal pain. *J Rheumatol* 1988;15:348-355.

97. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31(3):315-324.

98. Fries JF. Aging, illness, and health policy: Implications of the compression of morbidity. *Perspect Biol Med* 1988;31(3):407-428.

99. McShane DJ, Fries JF. The chronic disease data bank--the ARAMIS experience. *Proceedings of the IEEE* 1988;76(6):672-679.

100. Albridge KM, Standish J, Fries JF. Hierarchical time-oriented approaches to missing data inference. *Comput Biomed Res* 1988;21:349-366.

101. Lane NE, Fries JF. Relationship of running to osteoarthritis and bone density. *Compr Ther* 1988;14(2):7-15.

102. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire functional disability index in patients with rheumatoid arthritis. *J Rheumatol* 1988;15:1480-1488.

103. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. *Gastroenterology* 1989;96:647-655.

104. Fries JF, Green LW, Levine S. Health promotion and the compression of morbidity. *Lancet* 1989;I(March 4):481-483.

105. Edworthy SM, Bloch DA, McShane DJ, Segal MR, Fries JF. A "state model" of renal function in systemic

lupus erythematosus: Its value in the prediction of outcome in 292 patients. *J Rheumatol* 1989;16:29-35.

106. Fries JF. Advances in the management of rheumatic diseases: 1965-1985. *Arch Intern Med* 1989;149:1002-1011.

107. Lane NE, Bloch DA, Jones HH, Simpson U, Fries JF. Osteoarthritis in the hand: A comparison of handedness and hand use. *J Rheumatol* 1989;16:637-642.

108. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis: A national post-marketing perspective. *Arthritis Rheum* 1989;32(7):837-843.

109. Wysenbeck AJ, Bloch DA, Fries JF. Prevalence and expression of photosensitivity in systemic lupus erythematosus. *Ann Rheum Dis* 1989;48:461-463.

110. Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in polymyositis-Dermatomyositis: Results of a nationwide survey. *J Rheumatol* 1989;16(9):1218-1224.

111. Michel BA, Bloch DA, Fries JF. Weight-bearing exercise, over-exercise, and lumbar bone density over age 50 years. *Arch Intern Med* 1989;149:2325-2329.

112. Fries JF. Compression of morbidity: Near or far? *Millbank Mem Fund Q* 1990;67(2):208-232.

113. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. *Arthritis Rheum* 1990;33(1):121-130.

114. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Identification of patients at risk for gastropathy associated with NSAID use. *J Rheumatol* 1990;(suppl 20)17:12-29.

115. Lane NE, Bloch DA, Hubert HB, Jones H, Simpson U, Fries JF. Running, osteoarthritis, and bone density: Initial 2-year longitudinal study. *Am J Med* 1990;88(5):452-459.

116. Michel BA, Lane NE, Jones HH, Fries JF, Bloch DA. Plain radiographs can be useful in estimating lumbar bone density. *J Rheumatol* 1990;17:528-531.

117. Fries JF. A new sign (Fries' knees) for early detection of inflammation of the knee joint. *J Rheumatol* 1990;17(5):726.

118. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. *J Rheumatol* 1990;(suppl 22)17:12-15.

119. Fries JF. The epidemiology of systemic lupus erythematosus: 1950-1990 conceptual advances and the ARAMIS data banks. *Clinical Rheumatol* 1990;9(1).

120. Fries JF. The compression of morbidity: Progress and potential. *J Insurance Med* 1990;22(2):93-97.

121. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. *Arthritis Rheum* 1990;33(8):1065-1067.

122. Bloch DA, Michel BA, Hunder GG, McShane DJ, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. *Arthritis Rheum* 1990;33(8):1069-1073.

123. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990;33(8):1101-1107.

124. Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fauci AS, Fries JF, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. *Arthritis Rheum* 1990;1108-1113.

125. Fries JF, Hunder GG, Bloch DA, Michel BA, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 Criteria for the classification of vasculitis: summary. *Arthritis Rheum* 1990;33(8):1135-1136.

126. Fries JF, Singh GS, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. *Arthritis Rheum* 1990;33:1611-1619.

127. Fries JF. Long-term survival after renal crisis. *J Rheumatol* 1990;17(11):1572-1573.

128. Fries JF. Safety issues related to DMARD therapy. *J Rheumatol* 1990;17:14-17.

129. Fries JF. The epidemiology of NSAID gastropathy: The second most deadly rheumatic disease? *J Musculos Med* 1991;8(2):21-28.

130. Leigh JP, Fries JF. Education level and rheumatoid arthritis: Evidence from five data centers. *J Rheumatol* 1991;18:24-34.

131. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. *J Rheumatol* 1991;(suppl 28)18:6-10.

132. Singh G, Fries JF, Williams CA, Zatarain E, Spitz PW, Bloch DA. Toxicity profiles of disease-modifying anti-rheumatic drugs in rheumatoid arthritis. *J Rheumatol* 1991;18(2):188-194.

133. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early RA. *J Rheumatol* 1991;18(6):804-808.

134. Leigh JP, Fries JF. Occupation, income, and education as independent correlates of arthritis in four national probability samples. *Arthritis Rheum* 1991;34(8):984-995.

135. Fries JF, Williams CA, Bloch DA, Michel BA. NSAID-associated gastropathy: Incidence and risk factor models. *Am J Med* 1991;91(3):213-222.

136. Fries JF, Williams CA, Morfeld D. Improvement in intergenerational health. *Amer J Pub Health* 1991;81(12):109-112.

137. Fries JF, Williams CA, Bloch DA. The relative toxicity of non-steroidal anti-inflammatory drugs (NSAIDs). *Arthritis Rheum* 1991;34(11):1353-1360.

138. Fries JF. The hierarchy of Quality-of-Life Assessment, the Health Assessment Questionnaire, and issues mandating development of a Toxicity Index. *Controlled Clin Trials*, 1991;Vol. 12, No. 4, pgs. 106S-117S.

139. Leigh JP, Fries JF. Mortality Predictors among 263 rheumatoid arthritis patients. *J Rheumatol* 1991;18(9):1307-1312.

140. Michel BA, Lane NE, Bloch DA, Jones HH, Fries JF. Effect of changes in weight-bearing exercise on lumbar bone mass after age fifty. *Ann Intern Med*, 1991;23:397-401.

141. Seleznick MJ, Fries, JF. Variables associated with decreased survival in systemic lupus erythematosus. *Semin Arthritis Rheum* 1991;21(2):73-80.

142. Leigh JP, Fries JF. Health habits, health care use and costs in a sample of retirees. *Inquiry* 1992;29:44-54.

143. Leigh JP, Fries JF. Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. *Ann Rheum Dis* 1992;51:581-587.

144. Michel BA, Bloch DA, Fries JF. Physical activity and fractures over the age of fifty years. *Int Orthop* 1992;16:87-91.

145. Fries JF. Strategies for reduction of morbidity. *Am J Clin Nutr* 1992;55:1257S-1262S.

146. Ramey DR, Raynauld JP, Fries JF. The Health Assessment Questionnaire 1992; status and review.

Arthritis Care Research 1992;5:119-129.

147. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1994;37;12:1761-1769.

148. Fries JF, Tilton-Fries S, Parcell, Harrington H. Health risk changes with a low-cost individualized Health promotion program: effects at up to 30 months. *Am J Health Promotion* 1992;6:364-371.

149. Leigh JP, Richardson N, Beck R, Kerr C, Harrington H, Parcell CL, Fries JF. Randomized controlled study of a senior health promotion program: The Bank of America study. *Arch Intern Med* 1992;152:1201-1206.

150. Leigh JP, Fries JF, Hubert HB. Gender and race differences in the correlation between body mass and education in the 1971-1975 NHANES I. *J Epidemiol Community Health* 1992;46:191-196.

151. Michel BA, Fries JF, Bloch DA, Lane NE, Jones HH. Osteophytosis of the knee: Association with changes in weight-bearing exercise. *Clinical Rheumatol* 1992;11(2):235-238.

152. Fries JF, Seibold JR, Medsger TA. Photopheresis for scleroderma? No! *J Rheumatol* Editorial, 1992;19(7):1011-13.

153. Leigh JP, Fries JF, Parikh N. Severity of disability and duration of disease in rheumatoid arthritis. *J Rheumatol* 1992;19(12):1906-1911.

154. By the International Study Group for Behcet's Disease. Evaluation of diagnostic (classification) criteria in behcet's disease - towards internationally agreed criteria. Chairman of Working Party (Sept. 1989) Fries, *Br J Rheumatol* 1992;31:299-308.

155. Michel BA, Lane NE, Bjorkengren A, Bloch DA, Fries JF. Impact of running on lumbar bone density: a 5-year longitudinal study. *J Rheumatol* 1992;19:1759-63.

156. Fries JF. The chronic disease data bank model: A conceptual framework for the computer-based medical record. *Comp and Biomedical Research* 1992;25:586-601.

157. Leigh JP, Fries JF. Disability in occupations in a national sample. *Am J Public Health* 1992;82:1517-1524.

158. Lubeck DP, Fries JF. Changes in quality of life among persons with HIV infection. *Qual Life Res* 1992;1:359-366.

159. Fries JF, Ramey DR. Platonic outcomes. *J Rheumatol* Editorial, 1993;20:415-417.

160. Lubeck DP, Fries JF. Health status among persons with HIV infection: a community-based study. *Medical Care* 1993;31(3):269-276.

161. Leigh JP, Fries JF. Associations among healthy habits, age, gender, and education in a sample of retirees. *Int'l J of Aging and Human Devel* 1993;36:139-155.

162. Lane NE, Michel B, Bjorkengren A, Oehlert J, Shi H, Bloch DA, Fries JF. The risk of osteoarthritis with running and aging: a five-year longitudinal study. *J Rheumatol* 1993;20:461-468.

163. Hubert HB, Bloch DA, Fries JF. Risk factors for physical disability in an aging cohort: the NHANES I epidemiologic follow-up study. *J Rheumatol* 1993;20:480-488.

164. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease modifying anti-rheumatic drugs (DMARDs). *Arthritis Rheum* 1993;36:297-306.

165. Lubeck DP, Bennett CL, Mazonson PD, Fifer SK, Fries JF. Quality of life and health service use among HIV-infected patients with chronic diarrhea. *J Acquired Immune Deficiency Syndromes* 1993;6:478-484.

166. Fries JF, Bloch DA, Harrington H, Richardson N, Beck R. Two-year results of a randomized controlled

trial of a health promotion program in a retiree population: the Bank of America study. *Am J Med* 1993;94:455-462.

167. Leigh JP, Fries JF. Tobit, fixed effects, and cohort analyses of the relationship between severity and duration of rheumatoid arthritis. *Soc Sci Med* 1993;36:1495-1502.

168. Leigh JP, Ward MM, Fries JF. Reducing attrition bias with an instrumental variable in a regression model: results from a panel of rheumatoid arthritis patients. *Statistics in Med* 1993;12:1005-1018.

169. Fries JF, Koop CE, Beadle CE, Cooper PP, England MJ, et al. Reducing health care costs by reducing the need and demand for medical services. *N Engl J Med* 1993;329:321-325.

170. Belmonte-Serrano MA, Bloch DA, Lane NE, Michel BE, Fries JF. The relationship between spinal and peripheral osteoarthritis and bone density measurements. *J Rheumatol* 1993;20:1005-1013.

171. Fries JF, Ramey DR, Singh G, Morfeld D, Bloch DA, Raynauld JP. A reevaluation of aspirin therapy in rheumatoid arthritis (RA). *Arch Intern Med* 1993;153:2465-2471.

172. Ward MM, Leigh JP, Fries JF. Progression of functional disability in patients with rheumatoid arthritis. *Arch Intern Med* 1993;153:2229-2237.

173. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. *J Rheumatol* 1993;20:1666-1669.

174. Fries JF, Williams CA, Ramey DR, Bloch DA. The relative toxicity of alternative therapies for rheumatoid arthritis: implications for the therapeutic progression. *Sem in Arthritis and Rheum* 1993;23:68-73.

175. Clarke AE, Esdaile JM, Bloch DA, LaCaille D, Danoff DS, Fries JF. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs. *Arthritis Rheum* 1993;11:1548-1559.

176. Raynauld JP, Bloch DA, Fries JF. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. *J Rheumatol* 1993;20:1524-1526.

177. Raynauld JP, Lee L, Kornfeld P, Fries JF. Unilateral ptosis as an initial manifestation of d-penicillamine induced myasthenia gravis. *J Rheumatol* 1993;20:1592-1593.

178. Leigh JP, Fries JF. Correlations between education and arthritis in the 1971-1975 NHANESI. *Soc Sci Med*, 1994;38:575-583.

179. Fries JF, Harrington H, Edward R, Kent LA, Richardson N. Randomized controlled trial of cost reductions from a health education program: the California Public Employees' Retirement System (PERS) study. *Am J health Promotion* 1994;8:216-223.

180. Fries JF, Hochberg MC, Medsger TA, Hunder GG, Bombardier C, and the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Criteria for rheumatic diseases. *Arthritis Rheum* 1994;37:454-462

181. Lubeck DP, Fries JF. Changes in health status after one year for persons at-risk for and with HIV infections. *Psychol Health* 1994;9:79-92.

182. Edworthy, Bloch, Brant, Fries JF. Detecting treatment effects in patients with rheumatoid arthritis - the advantage of longitudinal data. *J Rheumatol* 1993;20 (1):40-44.

183. Singh G, Ramey DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal anti-inflammatory agents. *Pharmac Ther* 1994;62:175-191.

184. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;37(4):481-494.

185. Fries JF, Singh G, Morfeld D, Hubert HB, Lane NE, Brown Jr. BW. Running and the development of

disability with age. *Ann Intern Med* 1994;121:502-509.

186. Leigh JP, Fries JF. Arthritis and mortality in the epidemiological follow-up to the national health and nutrition examination survey I. *Bull N Y Acad Med* 1994;71(1):69-86.

187. Hubert HB, Fries JF. Predictors of physical disability after Age 50. Six-year longitudinal study in a runners club and a university population. *Ann Epidemiol* 1994;4(4):285-294.

188. Montgomery EB, Jr., Leiberman A, Singh G, Fries JF. Patient education and health promotion can be effective in Parkinson's Disease: A randomized controlled trial. *Am J Med* 1994;97:429-435.

189. Leigh JP, Fries JF. Education, gender, and the compression of morbidity. *Int J Aging Hum Dev* 1994;39(3):233-246.

190. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. *Arthritis Rheum* 1994;37(12):1761-1769.

191. Leigh JP, Lubeck DP, Farnham PG, Fries JF. Hours at work and employment status among HIV-infected patients. *AIDS* 1995;9:81-88.

192. Sampalis JS, Esdaile JM, Medsger TA, Partridge AJ, Yeadon C, Senecal JL, Myhal D, Harth M, Gutkowski A, Carette S, Cush JJ, Fries JF. A controlled study of the long-term prognosis of adult still's disease. *Am J Med* 1995;98:384-388.

193. Fries JF. ARAMIS and toxicity measurement. *J Rheumatol* 1995;22:995-997.

194. Fries JF. The toxicity of anti-rheumatic drugs: Problems and solutions. *Proc R Coll Physicians Edinb* 1995;25:398-405.

195. Fries JF. Physical activity, the compression of morbidity, and the health of the elderly. *J R Soc Med* 1996;89:64-67.

196. Fries JF, Singh G, Morfeld D, O'Driscoll P, Hubert H. Relationship of running to musculoskeletal pain with age: A six-year longitudinal study. *Arthritis Rheum* 1996;39:64-72

197. Fries JF. Effectiveness and toxicity considerations in outcome-directed therapy in rheumatoid arthritis. *J Rheumatol* 1996, 23(44):102-106.

198. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying anti-rheumatic drug-based treatment strategies. *Arthritis Rheum* 1996, 39(4):616-662.

199. Distel M, Mueller C, Bluhmki E, Fries JF. Safety of meloxicam: A global analysis of clinical trials. *Br J Rheumatol* 1996;35(suppl1):68-77.

200. Fries JF. Prevention of Osteoporotic Fractures: Possibilities, the role of exercise, and limitations. *Scan J Rheumatol* 1996;(suppl103):6-12.

201. Gironimi G, Clarke AE, Hamilton VH, Danoff DS, Bloch DA, Fries JF, Esdaile JM. Why Health Care Costs More in the US. Comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal. *Arthritis Rheum* 1996;39(6):979-987.

202. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. *Arch Intern Med* 1996;156:1530-1536.

203. Henry D, Lim LLY, Rodriguez LAG, Gutthann SP, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries JF. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. *BMJ* 1996;312:1563-1566.

204. Sampalis JS, Medsger TA, Fries JF, Yeadon C, Senecal JL, Myhal D, Harth M, Gutkowski A, Carette S,

Beaudet F, Partridge AJ, Esdaile JM. Risk factors for adult Still's Disease. *J Rheumatol* 1996;23:2049-2054.

205. Fries JF. Exercise and the health of the elderly. *Am J Geriatric Cardiology* 1997;6(3):24-32.

206. Fries JF, Williams CA, Singh G, Ramey DR. Response to therapy in rheumatoid arthritis is influenced by immediately prior therapy. *J Rheumatol* 1997;24(5):838-844.

207. Fries JF, Carey C, McShane DJ. Patient education in arthritis: Randomized controlled trial of a mail-delivered program. *J Rheumatol* 1997;24(7):1378-1383.

208. Leigh JP, Lubeck DP, Fries JF. Potential and actual workdays lost among patients with HIV. *J Acquired Immune Deficiency Syndromes and Human Retrovirology* 1995;8(4):392-398.

209. Leigh JP, Lubeck DP, Farnham P, Fries JF. Absenteeism and HIV infection. *Appl Economics Letters* 1997;4:275-280.

210. Fries JF, Ramey DR. Arthritis specific global health analog scales assess generic health related quality-of-life in patients with rheumatoid arthritis. *J Rheumatol* 1997;24(9):1697-1702.

211. Fries JF. Reducing the need and demand for medical care: Implications for quality management and outcome improvement. *Quality Management in Health Care* 1997;6(1):34-44.

212. Lubeck DP, Fries JF. Assessment of quality of life in early stage HIV-infected persons: data from the AIDS Time-Oriented Health Outcome Study (ATHOS). *Qual Life Res* 1997;6:494-500.

213. Fries JF, Koop CE, Sokolov J, Beadle CE, Wright D. Beyond health promotion: reducing need and demand for medical care. *Health Affairs* 1998;17(2):70-84.

214. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. *N Engl J Med* 1998; 338(15):1035-1041

215. Lane N, Oehlert J, Bloch DA, Fries F. Relationship of running to osteoarthritis of the knee and hip...a 9 year longitudinal study. *J Rheum* 1998; 25(2):334-341.

216. Fries JF. Quality-of-life considerations with respect to arthritis and nonsteroidal anti-inflammatory drugs. *Am J Med* 1998;104(3A):14-20.

217. Williams CA, Bloch DA, Sibley J, Haga M, Wolfe F, Raynauld JP, Singh G, Hickey AR, Fries JF. Lymphoma and leukemia in rheumatoid arthritis: Are they associated with azathioprine, cyclophosphamide, or methotrexate? A matched case-control study in the Arthritis, Rheumatism and Aging Medical Information System (ARAMIS) population. *J Clin Rheum* 1996; 2(2): 64-72.

218. Fries JF, McShane D. Reducing Need and Demand for Medical Services in High-Risk Persons: A Health Education Approach. *Western J Med* 1998;169(4):201-207.

219. Ward MM, Fries JF. Trends in Antirheumatic Medication Use Among Patients with Rheumatoid Arthritis, 1981 – 1996. *J Rheum* 1998;25(3):408-416.

220. Fries JF. Safety, Cost and Effectiveness Issues with Disease Modifying Anti-rheumatic Drugs in Rheumatoid Arthritis. *Ann Rheum Dis* 1999;58:(Suppl I) 186-189.

221. Fries JF. Current Treatment Paradigms in Rheumatoid Arthritis. *Rheumatology* 2000;39(Suppl 1):30-35.

222. Fries JF. Compression of Morbidity in the Elderly. *Vaccine* 2000;18:1584-1589.

223. Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling Therapeutic Strategies in Rheumatoid Arthritis: Use of Decision Analysis and Markov Models. *J Rheumatol* 2000;27(3):644-652.

224. Ortendahl M, Schettler JD, Fries JF. Factors Influencing Length of Time Taking Methotrexate in Rheumatoid Arthritis. *J Rheumatol* 2000;27(5):1139-1147.

225. Welch V, Singh G, Strand V, Fries J, Boers M et al. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. *J Rheumatol* 2001;28(5):1188-1191.

226. Fries JF. Aging, Cumulative Disability, and the Compression of Morbidity. *Comp Ther*, 2001;27(4):322-329.

227. Hubert HB, Bloch DA, Oehlert JW, Fries JF. Life-Style Habits and Compression of Morbidity. *J Gerontol Med Sciences*;2002; 37A(6):M347-351.

228. Fries JF. Successful aging – an emerging paradigm of gerontology. *Clin Geriatr Med*, 2002;18:1-12.

229. Hurst S, Kallan MJ, Wolfe FJ, Fries JF. Methotrexate, Hydroxychloroquine, and Intramuscular Gold in Rheumatoid Arthritis: Relative Area Under the Curve Effectiveness and Sequence Effects. *J Rheumatol* 2002;29(8):1639-45.

230. Ortendahl M, Holmes T, Schettler J, **Fries JF**. The Methotrexate Therapeutic Response in Rheumatoid Arthritis (RA). *J Rheumatol* 2002;29:2084-91.

231. **Fries JF**, Wolfe F, Apple R, Erlich H, Bugawan T, Holmes T, Bruce B. HLA-DRB1 Genotype Associations in 793 Caucasian Inception Cohort Patients with Rheumatoid Arthritis (RA): Frequency, Severity, and Treatment Bias. *Arthritis Rheum*, 2002;46(9):2320-2329.

232. Ortendahl M, **Fries JF**. Time-related issues with application to health gains and losses*. Journal of Clinical Epidemiology* 2002;55:843-848.

233. Wang BWE, Ramey D, Schettler JD, Hubert HB, **Fries JF**. Postponed Development of Disability in Elderly Runners: A 13-Year Longitudinal Study. *Arch Intern Med* 2002;162:2285-2294.

234. Bruce B, **Fries JF**. The Stanford Health Assessment Questionnaire: A Review of Its History, Issues, Progress, and Documentation. *J Rheumatol* 2003;30(1):167-178.

235. **Fries JF**. Aging, natural death, and the compression of morbidity. 1980. *Bull World Health Organ*. 2002;80(3):245-50.

236. Leigh JP, **Fries JF**. Frailty and education in the Hispanic Health and Nutrition Examination Survey. *J Health Care Poor Underserved*. 2002 Feb;13(1):112-27.

237. Bruce Bonnie, **Fries James F**. The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Health and Quality of Life Outcomes 2003, I:20.

238. **Fries JF.** Measuring and Monitoring Success in Compressing Morbidity. *Annals Int Med* 2003;139(5):455-459.

239. **Fries JF**, Holmes T, Bruce B. Rates of Serious GI Events from Low Dose Use of Acetylsalicylic Acid (ASA), Acetaminophen (APAP), and Ibuprofen (IBU) in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients. *J Rheumatol* 2003, Oct;30(10):2226-33.

240. **Fries JF**, Krishnan E. Equipoise, Design Bias, and Randomized Controlled Trials. *Arthritis Res Ther* 2004;6:R250-R255.

241. Lorig KR, Ritter PL, Laurent DD, **Fries JF**. Long-Term Randomized Controlled Trials of Small-Group and Tailored Print Arthritis Self-Management Interventions. *Medical Care* 2004;42(4):346-354.

242. **Fries JF**, Murtagh K, Bennett M, Zatarain E, Lingala B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. *Arthritis Rheum* 2004;50(8):2433-40.

243. Krishnan E, **Fries JF**. Reduction in long-term functional disability in Rheumatoid Arthritis 1977-1998: longitudinal study of 3035 patients. Am J Med 2003;115 (5):371-376.

244. Krishnan E, **Fries JF**. Measuring effectiveness of drugs in observational databanks: promises and perils. *Arthritis Res Ther* 2004;6:1-4.

245. Krishnan E, Murtagh K, Bruce B, Cline D, Singh G, **Fries JF**. Attrition Bias in Rheumatoid Arthritis Databanks: A Case Study of 6346 Patients in 11 Databanks and 65,649 Administrations of the Health Assessment Questionnaire. *J Rheumatol* 2004;31(7):1320-6.

246. Krishnan E, Tugwell P, **Fries JF**. Percentile benchmarks in patients with rheumatoid arthritis: Health Assessment Questionnaire as a quality indicator (QI). *Arthritis Res Ther* 2004;6:R505-R513. Available online http://arthritis-research.com/content/6/6/R505

247. **Fries, JF**. Heart-Healthy, Stroke-Free, Frailty, and the Compression of Morbidity. *Am J Preventive Med*, 2004. In press

248. Bruce B, **Fries, JF**. Longitudinal Comparison of the Health Assessment Questionnaire (HAQ) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). *Arthritis Care Research* 2004;51(5):730-737.

249. Daviglus ML, Liu K, Pirzada A, et al. Cardiovascular Risk Profile Earlier in Life and Medicare Costs in the Last Year of Life. *Arch Intern Med* 2005;165:1028-1034.

250. Berk D, Hubert HB, Fries JF. Associations of changes in exercise level with subsequent disability among seniors – A 16-year Longitudinal Study. *J Gerontol: Med Sciences.* 2005, in press.

251. Hueber W, Kidd BA, Toomooka BH, et al. Antigen Microarray Analysis Defines Subtypes of Rheumatoid Arthritis. *Arthritis Rheum* 2005, in press.

ARTICLES IN REFEREED CONFERENCE PROCEEDINGS

1. Fries JF. Measuring the quality of life in relation to arthritis therapy, in Proceedings of a symposium supported by an education grant from Pfizer Laboratories: *A Special Report: The State of the Art in Arthritis Therapy*. New York, Custom Communications, 1983, pp 49-56.

2. Fries JF. Panel Discussion: New functional measures: Do they overcome problems and how can they be improved? *Proceedings: Early Decisions in DMARD Development*. Published by the Arthritis Foundation, September 29-30, 1988, pp 127-129.

3. Fries JF. Forecasting and measurement of the HIV/AIDS epidemic, in LeVee WN (ed): *Conference Proceedings: New Perspectives on HIV-Related Illnesses: Progress in Health Services Research*. U.S. Department of Health and Human Services, Government Printing Office, 1989, pp 128-131.

4. Fries JF. NSAID-induced GI damage: risk and risk factors. *New Standards in Arthritis Care* 1992;April

5. Fries JF. Assessing and understanding patient risk. *Scand J Rheumatol* 1992;Suppl.92:23-26.

6. Fries JF. A new treatment approach DMARD-based sequential therapy. *Hospital Practice* 1995;23-30. A Special Report for Primary Care Physicians; Diagnosis and Treatment of Rheumatoid Arthritis.

7. Fries JF. NSAID-related adverse events: The view from the ARAMIS databanks. *New Insights into Anti-inflammatory Therapy and its Benefits* (Symposium Proceedings) 1994;41-47.

8. Fries JF. Toward an understanding of NSAID-related adverse events: The contribution of longitudinal data. *Scand J Rheumatol* 1996;25 (Suppl 102):3-8.

9. Fries JF. Effectiveness and toxicity considerations in outcome-directed therapy in rheumatoid arthritis. *Focus on Rheumatology* 1996;3:60-61.

10. Fries JF. Vision: The rebirth of individual autonomy in the field of health. *The European Proprietary Medicines Manufacturers' Association (AESGP) 33rd Annual Meeting, From Paternalism to Autonomy -*

The Importance of Responsible Self-Medication, Budapest, Hungary, 18-21 June 1997, Pgs. 24-31.

11. Fries, JF. How may quality of life for rheumatoid arthritis patients be enhanced by current and future treatments? *Rheumatology* 1999;38(suppl.2)35-40.

REVIEWS, EDITORIALS, AND INVITED NON-REFEREED PAPERS

1. Fries JF. A data bank for the clinician? Editorial. *N Engl J Med* 1976;294:1400-1402.

2. Fries JF. Education for outcome. Editorial. *J Rheumatol* 1978;5:1-2.

3. Liang MH, Fries JF. Containing costs in chronic disease: Monitoring strategies in the gold therapy of rheumatoid arthritis. Editorial. *J Rheumatol* 1978;5:241-244.

4. Fries JF, Loftus EF. Informed consent: Right or rite? *CA: A Cancer Journal for Clinicians* 1979;29:316-318.

5. Fries JF. The microvascular pathogenesis of scleroderma: An hypothesis. Editorial. *Ann Intern Med* 1979;91:788.

6. Fries JF. *Prospects for Health and Longevity, in The American Council of Life Insurance: A Vision for America*. Harriman, New York, 1981, May 27-29.

7. Fries JF. The compression of morbidity, Benjamin Gompertz, the Two Types of Chronic Disease, and Health Policy, in Somers AR, Somers HM: *Proceedings: Exploring New Frontiers of U.S. Health Policy*. New Jersey, 1984, pp 3-13.

8. Fries JF. The reactive enthesopathies, in Cotsonas, Jr NJ: *Disease-A-Month*. Chicago, Illinois, year Book Medical Publishers, Inc., XXXI:I, 1985, pp 5-46.

9. Seleznick M, Feigenbaum P, Wright V, Fries JF. Psoriatic arthritis subsets: A cluster analysis. *Rheumatology - 85*. Elsevier Science Publishers, New York, 1985, pp 309-312.

10. Fries JF. Measurement of the Quality of Life. Development of the Health Assessment Questionnaire (HAQ). *Rheumatology - 85*. Elsevier Science Publishers, New York, 1985, pp 409-414.

11. Fries JF. The compression of morbidity. *World Health Forum: An International Journal of Health Development* 1985;6(1):47-51.

12. Fries JF. Post-marketing drug surveillance: Are our priorities right? *J Rheumatol* 1988;15:389-390.

13. Fries JF. Book review of, Rothstein WG: *American Medical Schools and the Practice of Medicine*. *Science* 1988;240:1054-1055.

14. Fries JF. Epidemiology of gastropathy associated with NSAID use. *Physician Assistant* 1989;13:5-12.

15. Fries JF. Outcome assessment in the rheumatic diseases. *Jpn J Clin Pharmacol Ther* 1989;20(1):309-316.

16. Fries JF, Singh G, Bloch DA, Calin A. The natural history of ankylosing spondylitis: Is the disease really changing? (Editorial) *J Rheumatol* 1989;16(7):860-863.

17. Fries JF. The sunny side of aging. *JAMA* 1990;263(17):2354-2355.

18. Fries JF, Spitz PW, Bloch DA, Williams CA. Factors in the duration and discontinuation of treatment with nonsteroidal anti-inflammatory medications. *Excerpta Medica* 1991;Vol3 (supl.A):51-62.

19. Roth SH, Fries JF, Abadi IA, Hubscher O, Mintz G, Samara AM. Prophylaxis of nonsteroidal anti-inflammatory drug gastropathy: a clinical opinion. (Editorial) *J Rheumatol* 1991;18(7):956-958.

20. Fries JF. Minimizing the risk of NSAID-induced gastropathy in arthritis treatment. *Modern Med* 1991;59:68-76.

21. Fries JF. Choosing an Appropriate NSAID. *Drug Therapy* 1991;Oct:19-29.

22. Singh GS, Fries JF. Can liver test abnormalities in patients with rheumatoid arthritis be predicted by clinical symptoms? *J Rheumatol* Editorial 1992;19(7):1158-1159.

23. Clarke AE, Fries JF. Health status instruments and physical examination techniques in clinical measurement methodologies. *Current Science* 1992;4:145-152.

24. Fries JF, O'Driscoll PT, McShane DJ. Effects of new 1993 criteria for classification of AIDS. Editorial. *JAMA* 1993;269(22):2846-2847.

25. Fries JF. Compression of morbidity 1993: life span, disability, and health care costs. *Facts and Research in Gerontology* 1993;7:183-190.

26. Fries JF. Reducing need and demand. *Healthcare Forum Journal* 1993;Nov/Dec:18-22.

27. Fries JF. The chronic disease data bank model: a conceptual framework for directing medical care efforts toward improvement of the quality of life. *Quality of Life Newsletter* 1993;Number 7-8 (June 93 - Jan 94).

28. Fries JF, Ramey DR, Singh G. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum* 1994;37(12):1829-1834.

29. Fries JF. Health Care Demand Management. *Medical Interface* 1994;7(3):55-58.

30. Bellamy N, Boers M, Felson D, Fries J, Furst D, Henry D, Liang M, Lovell D, March L, Strand V, van der Linden S. Health Status Instruments / Utilities. *J Rheumatol* 1995;22:6 (Workshop Report).

31. Adler NE, Fries, JF, Hurowitz JC, et al. Are mind-body variables a central factor linking socioeconomic status and health? *Advances The Journal of Mind-Body Health* 1995;11(3):6

32. Fries JF. The toxicity of anti-rheumatic drugs: Problems and solutions. *Proc. R. Coll. Physicians Edinb* 1995;25:398-405.

33. Fries JF, Singh G. Glucocorticoids and joint destruction in rheumatoid arthritis. *N Engl J Med* 1995;333(23):1569-1570. Letter to the Editor.

34. Bellamy N, Boers M, Felson D, Fries JF, Furst D, Henry D, Liang M, Lovell D, March L, Strand V, van der Linden S. Health Status Instruments / Utilities. *J Rheumatol* 1995;22:1203-1207.

35. Fries JF, Schmitz MF. Need and demand reduction: Maximizing value for health care expenditures. *Benefits & Compensation International* 1996;26(3):21-24.

36. Fries JF. Will future elderly person experience more years of disability? Controversial Issues in Aging, edited by Andrew E. Scharlach and Lenard W. Kaye, 1996; Debate 19:209-220.

37. Fries JF. Non-steroidal anti-inflammatory drug safety: a view from the ARAMIS databank. *Current Opinion in Rheumatology* 1996;9(1):S3-S8.

38. Fries JF. Editorial: Can Preventive Gerontology Be on the Way? *Am J Public Health* 1997;87:1591-1592.

39. Fries JF. Editorial: Reducing the Need and Demand for Medical Services. *Psychosomatic Medicine* 1998;60:140-142.

40. Fries JF, Singh G, Ramey DR. The Clinical Epidemiology of Non-Steroidal Anti-Inflammatory Drug Gastropathy. *Clinical Significance and Potential of Selective COX-2 Inhibitors (William Harvey*

Conferences) William Harvey Press, 1998, pp. 57-64.

41. Fries JF. Reducing cumulative lifetime disability: the compression of morbidity. *Br J Sports Med* 1998;32:193-198.

42. Fries JF. The Epidemiology of NSAID Gastropathy. *J Clin Rheum* 1998;4(5)Supplement: S11-S16.

43. Fries JF. Reducing the need and demand for medical services. Psychosom Med 1998 Mar-Apr;60(2):140-2.

44. Fries JF. Osteoarthritis: New Insights, Part 1: The disease and its risk factors. (NIH Conference*) Annals of Internal Medicine* 2000;133:635-646.

45. Fries JF. Osteoarthritis: New Insights, Part 2: Treatment approaches. (NIH Conference*) Annals of Internal Medicine* 2000;133:726-737.

46. Fries JF. Political Physician. Absolute Advantage: The Workplace Wellness Magazine, 2002;1(6):16-17.

47. Fries, JF. Reducing Disability in Older Age. *JAMA*:2002;288(24):3164-3166.

48. Fries JF. Are There Limits to the Human Life Span? IUSSP Proceedings 2002. In press.

49. Fries JF, Lorig K, Holman HR. Patient Self-Management in Arthritis? Yes! *J Rheumatol* 2003;30:6.

.

50. Fries JF. The Sunny Side of Aging Redux. *JAMA* 2003, in press.

51. Fries JF. Aging Well: An Inside Look At The Compression of Morbidity. A Wellness Councils of America Interview: Aging Well. October, 2003.

52. Fries JF. New Instruments for Assessing Disability: Not Quite Ready for Prime Time. *Arthritis Rheum* 2004;50(10):3064-3067.

53. Fries JF. Compression of Morbidity: In Retrospect and in Prospect. *Alliance for Health & the Future*. Issue Brief 2005;2(2)1-5.

BOOKS

1. Fries JF, Holman HR. *Systemic Lupus Erythematosus*. Philadelphia, W.B. Saunders, 1975.

2. Vickery DM, Fries JF. *Take Care of Yourself: A Consumer's Guide to Medical Care*. Reading, Massachusetts, Perseus Books, 1975, 1980, 1986, 1990, 1993, 1996, 1998, 2001.

3. Calin A, Fries JF. *Ankylosing Spondylitis: Discussion in Patient Management*. Garden City, New York, Medical examination Publishing Co., Inc., 1978.

4. Fries JF. *Arthritis: A Comprehensive Guide*. Reading, Massachusetts, Perseus Books, 1980, 1986, 1990, 1994, 1999.

5. Fries JF, Ehrlich GE. *Prognosis: A Textbook of Medical Prognosis*. Bowie, Maryland, The Charles Press Publishers, 1980.

6. Lorig K, Fries JF. *The Arthritis Helpbook*. Menlo Park, California, Perseus Books, 1981, 1986, 1990, 1995, 1999.

7. Fries JF, Crapo LM. *Vitality and Aging*. San Francisco, California, W.H. Freeman Company, 1981.

8. Pantell R, Fries JF, Vickery D. *Taking Care of Your Child*. Reading, Massachusetts, Perseus Books,

1981, 1986, 1990, 1999, 2002.

9. Fries JF. *Milestones in Rheumatologic Patient Care: 1965-1985*. Humacao, Puerto Rico, Syntex Puerto Rico, Inc., 1988.

10. Fries JF. *Living Well*. Reading, Massachusetts, Perseus Books Publishing Company, 1989, 1993, 1999, 2000.

BOOK CHAPTERS

1. Fries JF. Scleroderma, in Conn HF (ed): *Current Therapy*. Philadelphia, W.B. Saunders Company, 1979, pp 658-661.

2. Fries JF. Clinical data banks and clinical decisions, in Statland BE, Bauer S (ed): *Computer-Assisted Decision Making Using clinical and Paraclinical (Laboratory) Data*. New York, Mediad, Inc., 1980, pp 101-107.

3. Combs BJ, Hales DR, Williams BK, Fries JF, Vickery DM. *An Invitation to Health: Your Personal Responsibility*. Menlo Park, California, Benjamin/Cummings, 1980, 1983, 1985.

4. Fries JF. ARAMIS: A national arthritis data resource, in: *Current Topics in Rheumatology: Epidemiology of the Rheumatic Diseases*. New York, Gower Medical Publishing Limited, 1984, pp 355-358.

5. Fries JF. How to use the computer clinically, in American Society of Internal Medicine in Cooperation with George Washington University Medical Center: *The Computer in Office Practice: Fundamentals and Concepts*. Roche Laboratories, Division of Hoffmann-La Roche, Part 2, Inc., 1984, pp 2-14.

6. Fries JF. The compression of morbidity, in Robinson PK, Livingston J, Birren JE (eds): *Aging and Technological Advances*. New York, Plenum Press, 1984, pp 169-187.

7. Fries JF. General approach to the rheumatic disease patient, in Kelley WN, Harris ED, Ruddy S, Sledge CB (eds): *Textbook of Rheumatology*. Philadelphia, Pennsylvania, W.B. Saunders Company, Vol 2, 1985, pp 361-365.

8. Fries JF. Approach to the patient with musculoskeletal disease, in Wyngaarden JB, Smith Jr LH (eds): *The Cecil Textbook of Medicine*. Philadelphia, PA, W.B. Saunders Company, 1985, pp 1891-1894.

9. Fries JF. Can health promotion enable people to live healthier lives into late life? in Carlson RJ, Newman B: *Issues & Trends in Health*. St. Louis, The C.V. Mosby Company, 1987, pp 236-241.

10. Fries JF. Approach to the patient with musculoskeletal disease, in Smith LH, Wyngaarden JB (eds): *The Cecil Textbook of Medicine*. Philadelphia, W.B. Saunders Company, 1988, pp 1977-1980.

11. Fries JF. Reduction of the national morbidity, in Lewis SJ: *Aging & Health: Linking Research and Public Policy*. Chelsea, Michigan, Lewis Publishers, Inc., 1989, pp 3-22.

12. Fries JF, Spitz PW. Quality of life studies: The hierarchy of patient outcomes, in Spilker B (ed): *Quality of Life Assessment for Clinical Trials*. New York, Raven Press Ltd., 1990.

13. Fries JF. The compression of morbidity: progress and potential, in Bergener M, Ermini M, Stahelin HB (eds): *Challenges in Aging*. Academic Press Inc., San Diego, California, 1990, pp 267-279.

14. Fries JF, Bellamy N: Introduction, in Bellamy N. *Prognosis in the Rheumatic Diseases*. Kluwer Academic Publishers, Hingham, Massachusetts, 1991, pp 1-10.

15. Fries JF. The workspan and the compression of morbidity, in Munnell AH: *Retirement and Public Policy*. Kendall/Hunt Publishing Company, Dubuque, Iowa, 1991, pp 159-171.

16. Fries JF. Approach to the patient with musculoskeletal disease. *Musculoskeletal and Connective Tissue diseases, Part XIX, Cecil Textbook of Med*, 1991;1488-1491.

17. Fries JF. Medical perspectives upon successful aging. *Successful Aging, Editors Baltes and Baltes*, 1992; pgs. 35-46.

18. Fries JF. Clinical implications of the relative therapeutic toxicity of medications used to treat rheumatoid arthritis. *Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment*, 1994; pgs. 403-414.

19. Fries JF, Leigh JP. Associations among Healthy habits, age, gender, and education in a sample of retirees. *Health and Health Care Utilization in Later Life, 1995; pgs. 21-38.*

20. Fries JF. Aging, Society, and Health. In: Bezold C. And Mayer E., eds*. Future Care: Responding to the Demand for Change*. New York: Faulkner & Gray, Inc. 1996:43-42.

21. Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 - Status and Review. Pharmacoeconomics and Quality of Life in Clinical Trials, Second Edition, edited by B. Spilker. New York: Raven Press, 1996;Chapter 25:227-237.

22. Fries JF. The Case for Healthy Aging and the Compression of Morbidity*. Healthy Aging, Challenges and Solutions.* Gaithersburg, Maryland, Aspen Publishers, Inc., 1999, pp. 45-61.

23. Fries JF. Drugs That Relieve Pain and Inflammation. *Primary Care Rheumatology.* Philadelphia, Pennsylvania, WB Saunders Company, 1999, pp. 87-96.

24. Harris JS, Fries JF. The Health Effects of Health Promotion. *Health Promotion in the Workplace*, Third Edition, edited by Michael P. O'Donnell. Albany, New York: Delmar, Thomson Learning, 2001,Chapter 1:1-22.

25. Fries JF. Morbidity Compression. *The Encyclopedia of Elder Care: The Comprehensive Resource on Geriatric and Social Care,* edited by Mathy D. Mezey, RN, EdD, FAAN. New York, Springer Publishing Company, 2001, pp 436-438.

26. Fries JF. Compression of Morbidity/Disease Postponement. *The Encyclopedia of Aging: A Comprehensive Resource in Gerontology and Geriatrics*, Third Edition, edited by George L. Maddox, New York, Springer Publishing Company, 2001, pp 234-236.

27. Harris JS, Fries JF. The health effects of health promotion. In O'Donnell M (ed) *Health Promotion in the Workplace (3rd Edition).* Albany, NY: Delmar Press, a division of Thomson Learning, 2001.

28. Fries JF. Helping People to Help Themselves: Reduction in Need and Demand for Medical Services. *Consumer Driven Healthcare*, R. Herzlinger, Ed, Harvard University Press. 2003, in press.

29. Fries JF. Proven Reduction of the Need and Demand for Medical Services: Healthtrac, Inc. *Consumer Driven Healthcare*, R. Herzlinger, Ed, Harvard University Press. 2003, pp 523-531.

30. Fries JF. Aging, Frailty, and the Compression of Morbidity: Definite Progress. *Longevity and Frailty*. Springer-Verlag, Berlin Heidelberg. April 2005